Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3861316 | 1.00 | KMT2A (0.49) | KMT2AMEN1POLBCRHBPCRHR2 | |
| SCHEMBL3858498 | 0.91 | KMT2A (0.43) | KMT2AMEN1POLBHCRTR2TSHR | |
| SCHEMBL3856014 | 0.91 | KMT2A (0.43) | KMT2AMEN1POLBHCRTR2TSHR | |
| SCHEMBL3858289 | 0.91 | KMT2A (0.43) | KMT2AMEN1POLBHCRTR2TSHR | |
| SCHEMBL3855998 | 0.91 | KMT2A (0.46) | KMT2AMEN1POLB | |
| SCHEMBL3860354 | 0.91 | KMT2A (0.46) | KMT2AMEN1POLB | |
| SCHEMBL3855449 | 0.91 | KMT2A (0.46) | KMT2AMEN1POLB | |
| SCHEMBL3860943 | 0.88 | KMT2A (0.46) | KMT2AMEN1POLB | |
| SCHEMBL3863242 | 0.88 | KMT2A (0.46) | KMT2AMEN1POLB | |
| SCHEMBL3853993 | 0.87 | KMT2A (0.41) | KMT2AMEN1TSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585871-B2 | 4-{[(6R)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 3-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 4-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; cytokine expression | WYETH (US) | 2009-09-08 | — | — | US | claimed |
| US-20060058337-A1 | Phenanthridine carbonyl phenols | WYETH (US) | 2006-03-16 | — | — | US | claimed |
| US-7585871-B2 | 4-{[(6R)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 3-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; 4-{[(6S)-8-fluoro-6-methylphenanthridin-5(6H)-yl]carbonyl}phenol; cytokine expression | WYETH (US) | 2009-09-08 | — | — | US | disclosed |
| US-20060058337-A1 | Phenanthridine carbonyl phenols | WYETH (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058337-A1 | Phenanthridine carbonyl phenols | MT-CO2, PAH, CBR3 | KMT2A 1282/4885MEN1 3644/4885POLB 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.